Engineered Antimicrobial Peptides Block SARS-CoV-2 Entry by Targeting ACE2 and TMPRSS2 | Research

The takeaway

Computationally mutated antimicrobial peptides showed ability to inhibit ACE2, TMPRSS2, and spike protein interactions, presenting a peptide-based approach to blocking SARS-CoV-2 cell entry.

Triple blockade
Engineered peptides target ACE2, TMPRSS2, and spike protein simultaneously, making viral escape through mutation more difficult

What the researchers found

Computationally designed antimicrobial peptide mutants showed potential to inhibit ACE2, TMPRSS2, and spike protein interactions, targeting multiple steps of SARS-CoV-2 cell entry.

Why it matters

Viral mutations can evade vaccines and drugs targeting a single protein. Peptides that block multiple entry points simultaneously would be much harder for the virus to escape, providing more durable antiviral protection.

The numbers in context

Four key receptors were targeted: ACE2, TMPRSS2, GRP78, and AT1R. Multiple databases were used including RCSB PDB, StraPep, and PhytAMP.

How the study worked

Computational mutagenesis of antimicrobial peptides. Molecular docking and binding affinity analysis against ACE2, TMPRSS2, and spike protein. Stability and interaction characterization.

Who was studied

N/A — computational modeling study

What this study cannot tell us

Computational study — predictions need experimental validation. In silico binding does not guarantee in vivo antiviral activity. Manufacturing and delivering multi-target peptides is challenging.

How to read the evidence

Preliminary evidence: computational design study requiring experimental validation for antiviral activity.

When this study was published

Published in 2024. Addresses ongoing need for broad-spectrum antiviral strategies.

The bigger picture

Antimicrobial peptides that also have antiviral properties represent a dual-defense approach. Engineering them to target multiple viral entry mechanisms creates peptide-based antivirals that could complement vaccines and address future pandemic threats.

Questions still open

Do these computationally designed peptides block SARS-CoV-2 entry in cell culture experiments?
Would multi-target peptide antivirals work against SARS-CoV-2 variants and future coronaviruses?
Can these peptides be delivered as nasal sprays for prophylactic antiviral protection?

Common questions

Can peptides fight viruses?

Yes — antimicrobial peptides can have antiviral properties by blocking viral entry into cells or disrupting viral membranes. These engineered peptides target three proteins involved in SARS-CoV-2 entry, potentially blocking infection at multiple steps.

Why target three proteins instead of one?

Viruses can mutate to evade drugs targeting a single protein. By designing peptides that block three different entry points (ACE2, TMPRSS2, and spike), the virus would need to mutate all three simultaneously to escape — making resistance much less likely.

Read the original research

Investigation of the mutated antimicrobial peptides to inhibit ACE2, TMPRSS2 and GRP78 receptors of SARS-CoV-2 and angiotensin II type 1 receptor (AT1R) as well as controlling COVID-19 disease.

Journal of biomolecular structure & dynamics, 43(4), 1641-1664

View on PubMed ↗Publisher’s paper ↗

Citation

Abedi Dorcheh, Fatemeh; Balmeh, Negar; Hejazi, Seyed Hossein; Allahyari Fard, Najaf. (2025). Investigation of the mutated antimicrobial peptides to inhibit ACE2, TMPRSS2 and GRP78 receptors of SARS-CoV-2 and angiotensin II type 1 receptor (AT1R) as well as controlling COVID-19 disease.. Journal of biomolecular structure & dynamics, 43(4), 1641-1664. https://doi.org/10.1080/07391102.2023.2292307